Additionally, p53 overexpression severely amplified the expression levels of the ANG II-induced cardiac hypertrophy markers ANP (ANG II versus GFP-p53+ANG II: 1.43±0.13 versus 3.01±0.92-fold change) and BNP (ANG II versus GFP-p53+ANG II: 2.55±0.67 versus 7.41±1.59; P<0.001) (Figure 4e), which demonstrated that p53 participated in hypertension-induced cardiac hypertrophy via modulating HSF2 and IGF-IIR. The gene discussed is TP53; the disease is cardiac hypertrophy.